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INTRODUCTION

With the advent of widespread use of coronary care units in the
late 1960 's, deaths due to arhythmias in patients with evolving myocardial infarctions were substantially reduced.

Left ventricular dysfunc-

tion, as manifest by pulmonary edema and cardiogenic shock, became recognized as the chief cause of in-hospital mortality.

Autopsy studies

revealed that car.diogenic shock occurred when the cumulative amount of
myocardial necrosis from old and new infarctions exceeded 40% of the
left ventricle (1,2).

More recently, residual ventricular function has

been shown to be a major predictor of long term survival after myocardial infarction (3).

Recognition of these facts has led to a large num-

ber of experimental and clinical studies in which pharmacologic, mechanical or surgical interventions have been employed to reduce the amount
of myocardial necrosis resulting fran coronary occlusion.
Stimulation of myocardial beta-1 receptors by catecholamines increases heart rate and contractile function and thereby oxygen consumption.

Some studies have proposed that catecholamines augment oxygen

consumption more than is necessary for the increased external work performed, and thus have an additional direct oxygen wasting effect (4).
Enhanced cardiac sympathetic nerve activity (5) and marked elevation of
circulating catecholamine levels have been demonstrated within minutes
of coronary eccl us ion ( 6).

Beta-blockers were thus an obvious first

choice in early experimental studies (7) and more recent clinical trials
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(8) designed to limit infarct size after coronary occlusion.
In current clinical practice, patients with coronary artery disease or hypertension, who are at higher than average risk for myocardial infarction, receive beta-blockers for periods of years.

There is a

weal th of experimental information about the effects of acute intravenously administered beta-blockade on infarct size, hemodynamics and
arhythmias resulting f'rom coronary occlusion.

In contrast, very 1 ittle

is known about the effects of chronic beta-blockade prior to coronary
occlusion on these parameters.

Investigations performed in animals

which have received chronic beta-blocker therapy (9) or chronic cardiac
denervation ( 10) suggest that long term interruption of beta-adrenergic
influences may confer more protection to ischemic hearts than may be
achieved with short term adrenergic interruption.

This study was de-

signed to compare the effects of acute vs. chronic beta-blockade on myocardial infarct size and hemodynamics in response to coronary occlusion.

LITERATURE REVIEW

Modification of Infarct Size - A Historical Perspective
Experimental studies attempting to measure and modify infarct size
have substantially improved our understanding of the basic pathophysiology of myocardial infarction.

Many different models of myocardial

infarction and methods of measuring infarct size have been employed and
later abandoned as knowledge has grown.

A few studies are particularly

noteworthy because they have demonstrated important new concepts which
serve as the foundation for present experimental and clinical investigations.
In 1971 Maroko et al. (7) ligated a branch of the left anterior
descending coronary artery and measured the magnitude of ST-segment elevation and CPK d epl etio n at sites within and remote from the area of
ischemic injury in anesthetized dogs.

They demonstrated; (1) that the

magnitude of epicardial ST-elevation 15 minutes after coronary occlusion
predicted the magnitude of cell death (as measured by CPK depletion) 24
hours later, (2) that interventions which enhanced myocardial contractil ity or heart rate ( isoproterenol, oubain, glucagon, bretyl ium,
pacing) or depressed coronary perfusion pressure ( hemmorhage) substantially increased EKG and enzymatic indices of myocardial injury, (3)
that propranolol, which decreases myocardial oxygen consumption by depressing heart rate and contractility, significantly decreased myocardial injury resulting from coronary occlusion, and lastly, (4) that
3
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the ability of isoproterenol and propranolol to alter the extent of injury persisted, but was blunted, when they were applied 3 hours after
coronary occlusion.

These were the first studies to demonstrate that

the extent of injury resulting from coronary occlusion could be altered
and suggested a time-dependent evolution of myocardial infarction.
The idea that all cells within a region of evolving myocardial
infarction did not die simultaneously was demonstrated by Riemer et al.
( 11).

The extent of transmural myocardial necrosis at the level of the

posterior papillary muscle was examined histologically in anesthetized
dogs subjected to circumflex coronary occlusions of varying duration.
They found that myocyte necrosis progressed in a wavefront from endocardium to epicard ium.

Irreversible cell death occurred rapidly in the

subendocardial region but was seen progressively later in the mid-wall
and subepicardial regions.

The relative proportion of transmural myo-

cardium which was ischemic but salvageable at 15 minutes, 40 minutes, 3
hours and 6 hours after coronary occlusion were 100%, 55%, 33%, and 16%
respectively.

When completed, the process of infarction spared a small

region of subepicardium.

Microvascular injury similarly progressed from

endocard ium to epicard ium but over a longer period of time. The most
severe injury occurred in endocard ial reg ions where endothelial swelling
and degeneration led to vascular occlusion which prevented reperfusion.
The major contribution of these studies was their definition of a very
narrow temporal window for therapeutic interventions during evolving
myocardial infarctions.
A major problem which hindered early studies was the fact that
unequivocal gross identification of myocardial infarcts becomes possible
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only after 24 hours of coronary occlusion ( 12).

Thus investigators

found it necessary to prolong the duration of their studies until the
processes of cell death and inflammation were sufficiently developed to
permit visual identification of regions of infarction.

Myocardial in-

farctions can be recognized earlier by light and electron microscopy,
but for practical reasons, these methods 1 imit quanti tation of necrotic
myocardium to progressively more circumscribed regions (i.e. the poster ior pa pill ar.y muscle (11)).

Epicard ial mapping of ST changes allows

early identification of ischemic injury at a particular site but does
not discriminate precisely the borders between normal and ischemic tissue and is only an indirect predictor of subsequent infarction.

A sig-

nificant technical advance occurred when macroscopic histochemical
stains, as originaly described by Nachlas and Shnitka in 1963 (12), were
rediscovered and popularized by Lie et al. (13) in 1975.

They recog-

nized that when myocardial muscle was immersed in colorless solutions of
certain tetrazolium salts (nitroblue tetrazolium and triphenyltetrazol ium chloride), a deeply colored precipitate was deposited on the
surface of viable tissue (NBT-blue, TTC-red), while infarcted tissue
remained unstained.

This technique precisely discriminates between in-

farcted and non-infarcted tissue as early as 3 hours after coronary ocd usion ( 14).

Several studies have shown that both NBT and TTC are as

accurate as the "gold standards" of histology and electronmicroscopy in
the identification of infarcted tissue ( 14-16).

Klein et al. ( 17) have

shown that failure of myocardial cells to stain with these tetrazolium
salts occurs because of the loss of dehydrogenase enzymes or their
necessary co-enzymes (NADINAIE).

Loss of co-enzymes is an earlier bio-
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chemical event than loss of dehydrogenases and accounts for the ability
to identify infarcted muscle within the first hours after coronary occlusion.

In comparison with earlier methods of quantitating the size of

experimental myocardial infarcts, tetrazollium salts allow experiments
of shorter duration and permit the visual identification and measurement
of myocardial

infar~ts

with the accuracy of histology and electron-

microscopy but with much greater ease.
It had been apparent to early investigators ( 18) and was later
rediscovered (19) that despite ligations of the same coronary artery at
a fixed anatomic site in the canine model, the proportion of the left
ventricle that became infarcted could vary widely among animals.

Lowe

et al. ( 19) were the first to propose that anatomic variation in the
size and distribution of a given coronary artery was the major reason
for this phenomenon.

They defined the myocardium perfused by a coronary

artery distal to its site of occlusion as the area at risk for infarction and suggested that in fare t size should be expressed in relation to
the size of the risk region.
A wide variety of methods to measure the size of the "area at
risk" were developed.

Ante-mortem techniques included the injection

into the left atrium of colored dyes, fluorescent vital stains, or
technetium-labelled albllllin microspheres which would identify the risk
region by its failure to take up the dye, fluoresce, or emit radiation
respectively (20-22).

Intracoronary injection of microfil, latex, water

soluble dyes, or barium sulfate gelatin allowed either direct or
"defect" definition of the risk region post-mortem (23,19,24,25).
Regardless of the method employed, a few important new concepts
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were consistently demonstrated.
amount of the

Widely recognized was the fact that the

left ventricle infarcted increased linearly as a function

of the size of the risk region (19,22,24,25).

When the area at risk was

less than 10-20% of the canine left ventricle, no infarction occurred
after coronary occlusion (22, 25-27).

Pharmacologic interventions could

shift this relation so that for any size risk region the mass infarcted
was significantly less (19,28).

It was also recognized that as the per-

fusion bed of the occluded coronary became larger, the proportion infarcted increased (25).

However, even with very large risk regions

there was always a small region of subepicardium which remained viable.
The ability of a pharmacologic intervention to salvage ischemic tissue
depends primarily on the size of the hypoperfused zone (22).

Experi-

mental animals with the smallest areas at risk had the greatest reduction in danage while those with the largest risk regions had the
least reduction in the proportion of the risk region infarcted.

Ad-

ditionally, spatial differences exist such that the most severe injury
occurs in basal a'ld subendocard ial portions of the risk region (25, 27).
An explanation for these regional differences in infarct size was
first proposed by Lowe et al. ( 19) and actually demonstrated by Jugdutt
et al. (25).

Using radioactive microspheres it was shown that col-

lateral blood flow within the area at risk was highest when the risk
region was small, in samples taken from the subepicardium, and in that
part closest to the apex (25, 27).

Conceptually, the relationship of the

size of the area at risk to its collateral blood flow was 1 ikened to
that of the volume of a sphere to its surface area ( 19).

The relative

proportion of the area at risk receiving collateral flow sufficient to
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prevent cell death is greatest when the risk region is small (25).

In

apical and subepicard ial regions, which are the surfaces of the sphere
interfacing with collateral vessels, the proportion of the risk region
which goes on to infarction is least.
An additional interesting finding which arose from these studies

was described by Becker et al. (26).

They found that in normal dog

hearts subjected to coronary occlusion, collateral blood flow to the
circtrnflex bed was consistently greater than that into the left anterior
descending bed.

Consequent! y when risk regions of equal size were gen-

erated by ligation of a coronary artery the amount infarcted was greater
after a left anterior descending occlusion than after circtrnflex occlusion.

By inference one would expect that interventions designed to

limit infarct size would be less effective when the left anterior descending is occluded as opposed to the circtrnflex.
Studies of the type cited thus far have evaluated the effects of
ischemia and interventions which modify it on quantitative measures of
cell necrosis.

However, no real benefit is achieved i f histologic sal-

vage of myocardium is unaccompanied by preservation or restoration of
contractile function.

Tennant and Wiggers (29) first recognized that

coronary occlusion caused the immediate loss of contraction within the
ischemic region.

Even tho'ugh myocardial function is lost rapidly, cell

death does not occur unless coronary occlusion is maintained for more
than 20 minutes (29).

Several investigators have recognized that recov-

ery of function after brief periods of ischemia C< 20 minutes) requires
2-3 days and is associated with gradual improvement of ul trastructural
and biochemical indices of reversible injury (30, 31 ).

Reperfusion after
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2 hours of coronary occlusion is accompanied by even longer periods of
functional recovery ( 14 days) which, on a regional basis, is never complete (32).

Braunwald has described reversibly injured myocardial mus-

cle as having been "stunned" by an ischemic insult (30).

Thus, the im-

provement in regional and global left ventricular function achieved by
interventions (i.e. reperfusion) which limit infarct size may not be
manifest for weeks.
In summary, these investigations have demonstrated that myocardial
infarction is a dynamic process which can be favorably modified within a
narrow temporal window.

Simple methods exist for accurately assessing

the anount of necrosis which occurs in laboratory animals.

The amount

of the left ventricle which becomes infarcted and the severity of ischemia within the per fusion bed of an occluded coronary artery are
largely determined by the anount of muscle served by that artery.

Myo-

cardium salvaged by reperfusion (and possibly by other interventions)
regains contractile function only after a period of days to weeks.

Effects of Acutely Administered Beta-blockade on Experimental and
Clinical Myocardial Infarction
Adequate rationale exists for proposing that the presence of betablockade may favorably alter the outcome of myocardial infarction.

In

nl.lllerous experimental studies involving several species, beta-blockers
have been administered just before or within hours of the onset of myocardial infarction.

As might be expected, variations in methods, exper-

imental models, species utilized and the specific beta-blocker given
have been accompanied by results that at times are conflicting.
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There are several studies which evaluate the ability of betablockers to protect myocardium subjected to prolonged periods of
coronary occlusion (i.e. 5 or more hours).

As mentioned earlier, Maroko

et al. (7) demonstrated that administration of propranolol (0. 5-2. O
mg/kg i.v.) just prior to ligation of the left anterior descending in
dogs resulted in less ST-elevation at 15 minutes and less CPK depletion
at 24 hours than seen in control animals.

When they performed ligations

of the circumflex in dogs, Rasmussen et al. (33) found that the proportion of the posterior papillary muscle infarcted after 24 hours was reduced :f'rom 85% to 52% in animals given 5 mg/kg of propranolol intraarterially 10 minutes before occlusion.

When propranolol therapy was

delayed to 3 hours after ligation, it was less than half as effective as
pre-treatment.

Fox et al. ( 34) investigated the effects of intravenous

propranolol (0. 5 mg/kg) administered 30 minutes after left anterior descending occlusion in anesthetized dogs.

Five hours after the onset of

infarction they noted significantly less CPK release, less QRS change,
and more rapid and substantial improvement in radionuclide images of the
perfusion deficit caused by coronary occlusion.

Downey et al. reported

that administration of 2 mg/kg propranolol at 6 hour intervals beginning
just after embolization of either the circunflex or anterior descending
produced substantial salvage of subepicardial ischemic muscle (35).
Recently, the relative effects of propranolol, timolol and metoprolol on
infarct size determined 6 hours after left anterior descending ligation
were compared (36).

When administered 15 minutes after coronary occl u-

sion all three agents reduced infarct size as compared with placebo, but
the beta-1 selective agents were twice as effective.
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In contrast, a few well done experimental studies are notable for
their failure to demonstrate protective effects of beta-blockers in myocardium subjected to long periods of ischemia.

Peter et al. (37) gave

high doses of propranolol (5 mg/kg iv) just prior to left anterior descending ligation and supplemented this with an infusion at 1.25
mg/kg/hr.

Identical degrees of CPK depletion were seen in

propranolol treated animals 24 hours later.

control and

More recent! y, the compara-

tive effects of metoprolol and pindolol administered at 30 to 90 minutes
after left anterior descending occlusion on coronary blood flow, left
ventricular function, and infarct size after 6 hours of ischemia were
measured (38).

Al though both beta-blockers decreased LV dP/dt and meto-

prolol decreased heart rate, neither agent produced changes in infarct
size or in coronary blood flow as measured by micro spheres.

Rogers et

al. performed the only experimental study of this type in primates.
They investigated the effects of sotalol on LV function and CPK depletion in baboons 24 hours after LAD ligation, and found no benefit (39).
Another group of experimental studies have investigated the effects of acute beta-blockade on infarct size resulting f'rom shorter periods of coronary occlusion (2 hours or less) followed by reperfusion.
At least 6 different investigations have been performed in anesthetized
dogs given various beta-blockers prior to or up to 2 hours after coronary ligation (40-45).

In comparison with reperfusion alone, substan-

tial additional reductions in infarct size varying f'rom 40-90S have been
seen.

The greatest additional benefit from adding beta-blockade to

reperfusion occurs when beta-blockade is administered prior to the onset
of ischemia, and when the time to reperfusion is brief.

By diminishing
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the oxygen requirements of ischemic myocytes beta-blockade delays cell
death so that more must!le can be salvaged at the time of re perfusion.
While the literature is more consistent in affirming the salutary
effects of acute beta-blockade on infarct size when combined with reperfusion, two exceptions bear mention.

Genth et al. (46) found that pin-

dolol, a beta-blocker with partial agonist activity, when administered
prior to a 90 minute coronary occlusion with subsequent reperfusion, did
not alter infarct size in dogs.

Because of its intrinsic sympathomi-

metic property, pindolol produced no changes in heart rate and may have
both blocked and stimulated beta receptors in ischemic muscle.
important is a study by Geary et al. done in baboons (47).

More

Al though

pretreatment with 2 mg/kg of propranolol produced substantial reductions
in heart rate and LV dP.fdt, no 1 imitation of infarct size was seen when
2 hows of coronary occlusion were followed by reperfusion.
The value of urgent beta blockade in patients experiencing acute
myocardial infarction has been studied in a host of clinical investigations (48-57,8).

In contrast to the animal studies cited thus far, a

number of uncontrolled variables have hindered these investigations.
Among them are; (1) inter-patient variability in the pathologic cause of
myocardial infarction, (2) difficulty in accurately measuring the
duration of ischemia prior to treatment, (3) differences in the coronary
artery involved, (4) variation in the severity of associated atherosclerosis in other coronary arteries, (5) diversity in the presence and
adequacy of collateral flow, (6) the variable presence and extent of
prior myocardial infarction, (7) pre-existing left ventricular dysfunction, and (8) difference in medications received chronically prior to
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the infarct.

Additionally, the ante-mortem methods of measuring infarct

size in patients that have been employed (serum CPK modelling, surface
EKG mapping, and planar radionucleide images) are at best indirect and
semi-quantitative measures of infarct size.
Despite these limitations, six clinical trials have reported reductions of enzymatic or EKG indices of infarct size (48-54).

In 3

large studies the incidence of primary ventricular fibrillation within
the first 48 hours of myocardial infarction was significantly reduced by
treatment with a beta-blocker (55-57).

These results are particularly

remarkable when it is realized that the dose of beta-blockers used have
generally been one-tenth of that found to limit infarct size in experimental animals.
Only one major clinical study failed to find a beneficial effect
of acute beta-blockade on infarct size (8).

In that study, propranolol

was given intravenously and later orally to patients presenting up to 18
hours after the onset of chest pain.

No improvement in enzymatic, EKG

or radionucleide estimates of infarct size was found.

The results of

that study are most likely explained by the fact that fewer than 2 per
cent of the patients studied received propranolol within 4 hours after
the onset of symptoms.

Myocardial Ischemia and Infarction After Chronic Cardiac Denervation or
Long-term Beta-blockade
Two separate lines of investigation suggest that chronic interruption of adrenergic stimulation may induce secondary adaptive changes
in cardiac muscle that would be beneficial during periods of ischemia.
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Resting myocardial oxygen consumption 2 weeks after cardiac denervation
(58) or ventricular sympathectomy (59) was approximately 50j less than
that in sham-operated dogs and was accompanied by significant reductions
in myocardial blood flow (59-61).

Despite increasing anounts of exter-

nal work, both myocardial oxygen consumption and coronary blood flow
continued to be one-half that of normal animals (59).

As a consequence

of this enhancement in the efficiency of energy utilization,

Barber et

al. (61) found that the minimal blood flow needed to prevent the death
of ischemic cardiac muscle was substantially lower after chronic cardiac
denervation.

A major reduction in coronary collateral resistance (62)

and a marked increase in collateral blood flow after coronary occlusion
(63) were reported after chronic ventricular sympathectomy.

Not sup-

risingly, a number of different studies have described dramatic reductions in infarct size, myocardial dysfunction and arhythmias resulting
f'rom coronary occlusion in chronically denervated animals ( 1O,60, 61, 6466).
Jones et al. (10) and Barber et al. (61) found that infarct size
following mid-LAD ligation was reduced in animals which underwent cardiac denervation immediately before coronary occlusion.

However, sig-

nificant further reductions in infarct size were seen in animals denervated 2-4 weeks prior to coronary occlusion.

Thomas et al. (64) com-

pared the effects of coronary occlusion on contractile function in dogs
with normally innervated, acutely denervated and cl'u"onically denervated
hearts.

Epicardial contractile force in the ischemic region was mini-

mally depressed in chronically denervated hearts but no similar protection was provided by acute denervation.
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With section of cardiac sympathetic nerves, Wallerian degeneration
of postganglionic fibers occw-s.

As a result, myocardial catecholamine

levels drop to less than 2% of normal in the first week after cardiac
denervation ( 67).

No similar depletion of catecholamines would be

anticipated in acutely denervated hearts subjected to coronary occlusion.

Local release of norepinephrine in response to ischemia might

be responsible for the intermediate preservation of ischemic myocardium
and regional function in

acutely denervated animals.

However, Jones et

al. ( 10) administered propranolol and i:tientolamine prior to coronary
occlusion in their acutely denervated dogs to prevent stimulation of
adrenergic receptors by locally released catecholamines.

They still

found that chronic denervation was significantly more effective in limiting infarct size.

This finding implies that metabolic alterations or

enhanced collateral flow after prolonged withdrawal of adrenerg ic neural
stimulation are more important mechanisms for protection of ischemic
myocardium.
In distinct contrast to previous studies is a recent investigation
by Lavallee et al. (68).

They reported that ligation of the circumflex

produced higher left ventricular end-diastolic pressures, diminished
collateral blood flow and larger myocardial infarctions in chronically
denervated dogs than was seen in normally innervated animals.

They at-

tributed the difference between their findings and those of earlier investigations to the fact that most previous studies were done in anesthetized animals while they produced coronary occlusions in concious
animals.

However, not all prior studies demonstrating beneficial ef-

fects of cardiac denervation on the cow-se of subsequent myocardial in-
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farction have been done in anesthetized animals.

Schaal et al. (65)

found that chronic cardiac denervation abolished the ventricular tachycardia seen in 9 of 10 control animals, after ligation of the anterior
descending, in conscious dogs.
Most experimental studies have shown that cardiac denervation
favorably affects infarct size, myocardial contractile function and
arhythmias after coronary occlusion.

In addition, prolonged denervation

seems to produce adaptive changes which afford the ischemic heart added
protection.

The salutary effects of acute denervation during ischemia

are similar to that achieved by acute beta-blockade ( 1 O).

A series of

experiments suggest that chronic beta-blockade may induce many of the
added benefits seen with chronic denerv ation.
In rabbits treated with propranolol for 4 or more weeks, electronmic:roscopy revealed substantially fewer mitochondria per cell than in
untreated animals (69).

In addition, the relative volume occupied by

capillaries was increased while the volume of the interstitial space was
diminished.

Besides demonstrating that the distance for diffusion of

oxygen from capillary to cell membrane is shortened, this study implies
a lower basal oxygen consumption after prolonged beta-blockade.

The

same treatment :regimen in another study (70) was found to markedly depress the activities of dopamine beta-hydroxylase and tyrosine hydroxylase (the rate limiting enzyme in norepinephrine synthesis) in sympathetic ganglia.

Depression of norepinephr ine synthesis by prolonged

beta-blockade might result in lower myocardial norepinephrine content
and thus decrease catecholamine mediated myocardial injury during ischemia.

Becker et al. (71) have shown that chronic beta-blocker therapy
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produces a functional alteration in the relation between beta receptors
and adenylate cyclase.

They found that prolonged beta-blockade l"educed

adenylate cyclase activity such that the Clllount of cyclic AMP produced
for any given extracellular concentration of catecholamine was signifi-

cantly diminished.

Wexler (72) found that 7 days aftel" withdrawal of

long-tenn propranolol therapy, massive doses of isoproterenol failed to
produce the extensive myocardial necrosis and mortality seen in rats not
previously treated with beta-blockers.

This protection was present at a

time when tissue and serl.111 propranolol levels would be unmeasurable.
A few studies have evaluated the effects of long-term betablockade in models of myocardial ischemia.

Manning et al. found that

both propranolol and oxprenolol, when administered orally for 3 weeks to
rats, resulted in an increased incidence of functional recovery after
periods of global ischemia in isolated perfused heart preparations (73).
Post-ischemic cellular levels of creatine phosphate and glycogen recov-

ered rapidly and more completely in animals previously beta-blocked than
in controls.

This beneficial action was seen as long as 48 hours after

beta-blocker withdrawal when serum d:rug levels were undetectable.
Nayler et al. (9) treated rabbits with propranolol for five days and
then subjected their hearts to 60 minutes of hypoxic perfusion in a
Langendol"f preparation.

They found much lower levels of CPK in the

coronary effluent and pronounced presel"vation of mitochondrial function
in the hearts pretreated with pl"opranolol as compal"ed with controls.
functional inhibition of the chronotl"opic response to isopl"otel"enol
could be demonstrated mol"e than 18 hours aftel" the last dose of pl"opranolol.

However, dramatic protection resulting f'rom beta-blocker

No
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therapy was seen as long as 72 hours after cessation of beta-blocker
adm in ist:r atio n.
Th:ree investigations have evaluated the effects of chronic betablockade on the course of subsequent coronary occlusion.

Of these, the

only study in large animals was that of Menken et al. (74).

They re-

ported that five days of atenolol therapy increased the ventricular fibrillation threshold and decreased the incidence of ventricular fibrillation after proximal circunflex occlusion in dogs.

Hearse et al. (75)

perfo:rmed LAD ligations in isolated perfused wo:rking rat hearts {»'"eviousl y treated with propranolol or acebutolol for 3 weeks.

One hour

after coronary occlusion, cardiogreen dye was infused into the patent
coronaries and the hearts were immediately frozen.

In this study, the

area at risk was identified by its failure to take up the green dye due
to inadequate antegrade or collateral coronary perfusion.

They found

that chronic beta-blockade resulted in substantially smaller risk regions than seen in controls, presumably on the basis of enhanced collateral flow.

However, the severity of ischemia within the ischemic

region, as measured by high energy phosphate levels, was not different
between groups.

Campbell et al. (76) ligated the left main coronary for

one hour in rats {»'"etreated with oxprenolol.

When coronary occlusion

occurred 1 hour after the last dose of oxprenolol, the incidence of ventricular fib:rillation and mortality were less than in control animals,
but no difference in infarct size was p:resent.

When the same expe:ri-

ments were perfo:rmed 16 hours after the last dose of oxprenolol, no
benefit was evident.

The failure of chronic beta-blocker therapy to

limit infarct size in this model can probably be attributed to the
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severity of the ischemic insult.

On the average, 48% of the ventricle

was in farcted one how after left main occlusion.

In addition to the

fact that a very large J)J"oportion of the ventricle was ischemic, the
severity of cellular injwy within this region was undoubtedly augmented
by the rapid heart rates in these animals, which often exceeded 400
beats per minute.
Only one clinical study has attempted to evaluate the effects of
prior beta-blocker therapy on infarct size in man (76).

In an investi-

gation involving 45 patients with acute myocardial infarction, 10 of
whom had chronically received any of a variety of beta-blockers, enzymatic measures of infarct size were made.

The time to the onset of

enzyme :release and the time to peak enzyme release were both significantly delayed by p:rior beta-blockade, although eventual infa:rct size
was not changed.

This data was interpreted as suggesting that beta-

blockade had delayed the onset of cell death in those patients.

In con-

trast, 3 large mul tic enter t:rial s involving timolol, propranolol and
metoprolol have all documented enhanced survival and a reduced incidence
of sudden cardiac death and reinfarction anong patients receiving these
beta-blockers on a chronic basis after myocardial infarction (78-80).
The mechanism fo:r this protection is unknown.

METHODS

Drug Treatment and Confirmation of Beta-blockade
Mongrel dogs employed in the study were divided into three treatment groups; group 1 (N•10) served as controls, group 2 (N•12) was
intravenously beta-blocked just prior to coronary occlusion and group 3
(N•11) was chronically beta-blocked prior to coronary occlusion.
3 animals :received 80 mg of nadolol twice daily for 16 days.

Group

They were

restricted to a na:r:row weight range (19-21.5 kg, mean•20.1 kg) to approximate an 8 mg/kg daily dose of nadolol.

Nadolol is a non-selective

beta-blocker which is 2 to 4 times more potent than p:rop:ranolol, but
lacks any direct myocardial depressant effects (81 ).

It is free of in-

trinsic sympathomimetic activity and was chosen because its half life of
elimination in dogs (4-5 h:rs, 82) is longer than that of any other betablocker.

Sixteen days of o:ral therapy were given because a similar

period produced marked protection after cardiac dene:rvation (10,61,64).
In one animal, 24 hours after a single 80 mg oral dose of nadolol, the
chronot:ropic response to a 2 ug!kg bolus of isoprote:renol was inhibited
by 51S.

In 5 additional experiments performed in our lab, this treat-

ment regimen inhibited the chronotropic response to the same bolus of
isoproterenol by 93S (71) and 87S when measured 12 hours after the last
oral dose of nadolol on days 7 and 14 of therapy, :respectively.

This

test dose of isoproterenol exceeds the chronotropic stimulus produced by
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maximal neural stimulation as demonstrated by experiments in our lab and
by Led sane et al. ( 84).
It was our intention that the degree of beta-blockade in the two
drug-treated groups be equivalent at the time of coronary occlusion.

In

this manner, differences in the degree of salvage of ischemic myocardium
in the two groups would not reflect dose-dependent differences in the
level of beta-blockade, but rather, effects achieved by different durations of therapy.

Therefore, acutely beta-blocked animals received suc-

cessive boluses of nadolol intravenously until they had less than a 10
beat per minute increase in heart rate in response to 2 ug/kg isoproterenol given intravenously.

Coronary occlusion in the chronically beta-

blocked dogs were performed approximately 12 hours after the last oral
dose of nadolol.

These animals were also given incremental doses of

nadolol intravenously until they had less than a 10 beat per minute increase in heart rate in response to the test dose of isoproterenol.

In

both drug-treated groups, titration of the degree of beta-blockade with
i .v. nadolol was performed approximately 15 minutes prior to coronary
occlusion.

Surgical Pr epar atio n
Animals in all treatment groups were an est he ti zed with pentobarbital and a tracheostomy tube was inserted for ventilation.

The animals

were ventilated with a Harvard respirator and arterial blood gases were
measured periodically to maintain pH in the range 7.35-7.45, with p02
greater than 60.

The right femoral vein and artery were isolated for
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venous access and measurement of arterial pressure.

The left femoral

artery was used for insertion of a Millar transducer-tipped catheter
which was advanced into the left ventricle for measurement of LVEDP,
left ventricular peak systolic pressure, and dP/dt.

ECG leads II, III,

and AVF were monitored to reflect changes in the posterior wall.
tachometer triggered by the ECG measured heart rate.

A bio-

Epicard ial tem-

perature was measured and maintained in the range 37-39 degrees celsius.
All hemodynamic and ECG measurements were recorded on a Gould 2800S recorder.

The first 30 minutes of the post-occlusion period were recorded

on magnetic tape for later analysis of arhythmias.
The chest was opened through the fourth left intercostal space,
and the pericardium opened with a small incision at the base of the
heart.

A segnent of the circumflex coronary artery was isolated within

1-2 cm of its origin, proximal to the first major marginal branch.

Experimental Protocol
In all animals control hemodynamic and ECG measurements were obtained 5 minutes prior to occlusion.

In drug-treated animals, these

pre-occlusion measurements were made after administration of i .v.
nadolol.

Coronary occlusion was achieved by tying a silk ligature about

the vessel.

In addition, an atraumatic occluder was placed on the

circumflex distal to the ligature when animals failed to manifest epicardial cyanosis or ST elevation.

Hemodynamic and ECG measurements were

made 15 minutes, 30 minutes, 1 hour, and hourly thereafter for the duration of the six hour period.

Three hours after occlusion, 0.5 mg/kg
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nadolol was given intravenously to drug-treated animals.
During the last hour of the experiment all animals received 5000
units of heparin, and a right carotid to circumflex shunt was placed to
permit reperfusion of the previously ischemic region (Figure 1).

The

carotid end of the shunt was created with a 50 cm length of tygon tubing
containing a cannulating-type electranagnetic flow probe.

5

(!UI

The tip of a

length of BF infant feeding tube was inserted into the circumflex

distal to the occluding ligature but proximal to any major branches.
After six hours of coronary occlusion, reperfusion through the shunt was
begun and shunt flow measured.

Measurement of Area at Risk and Infarct Size
After 15 minutes of reperfusion 1 ccfkg of a 1.5i solution or·
Evans blue in Ringer's solution was injected into the left atrium.

Be-

cause of the longer transit time for blood to reach the circumflex region via the shunt, a brief (2-3 second) interval occurred during which
the c i:rcumfl ex bed received dye-f'ree blood while the remainder of the
heart was blue stained.

At this time the hearts were fibrillated

electrically and Ringer's solution was infused into the circumflex cannula (6 cclmin) to keep dye out of the circumflex region while the heart
was excised.
Once removed, the heart was sliced in a "bread loaf" manner into 8
to 12 sections, in an apex to base direction.

The right ventricle and

atria were trimmed away and each slice blotted dry and weighed.

The

unstained regions within each ring represented the anatanic perfusion
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FIGURE 1
THE CAOOI'ID 10 CIRCUMFLEX SHUNT
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bed of the circumflex artery distal to the site of the occluding ligature, and was designated the area at risk for necrosis.

The lateral

margins of the area at risk were marked from epicardiurn to endocardium
on both surfaces of each slice with a felt tipped pen (Figure 2) .
To measure the size of the infarcted area each slice was soaked
for 20 minutes in a U solution of triphenyl tetrazoliurn chloride (TTC)
in phosphate buffer (23, 24).

Non-infarcted tissue on the surface of

each slice was stained a brick red by the tetrazoliurn dye, while infarcted tissue failed to stain.

Although TTC staining masked the Evans

blue-stained tissue, the margins of the area at risk, as defined by the
felt pen markings, remained visible (Figure 3).

Color slides of both

surfaces of each slice were made and later projected onto an Apple
graphics tablet for planimetry (using an Apple II+ computer and software).

From these images the :relative sizes of the left ventricular

cross sectional area, the area at risk and the area infarcted were
identified for both surfaces of each slice.

From these areas the ab-

solute weights of each :region were calculated and surnmated for the entire le ft ventricle.

Sta ti sties
Differences between groups in mortality and the incidence of ventrieular fibrillation, ventricular tachycardia, or high degree AV blook
were compared using Fisher's Exact Test.

Comparisons between groups in

the number of PVCs during the first 30 minutes of coronary occlusion
were evaluated using a one-way analysis of variance.

This same statis-
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FIGURE 2
THE METHOD FDR IDENTIFYING THE

AREA AT RISK

FIGURE 2. This is a photograph of the basal surface of a ring of
ventricular muscle at the level of the papillary muscles after infusion of Evan's blue dye. The unstained tissue in the left half of
this figure is the perfusion bed of the circumflex coronary artery
(i.e. the area at risk). Black lines marking the lateral margins of
the area at risk were placed with a felt-tipped pen. Note an extensive region of subendocardial halX)rrhage within the area at risk.
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FIGURE 3

THE MITTHOD OF IDENI'IFYING THE
AREA INFARCTED

FIGURE 3. This photograph was taken after the same slice of ventricular muscle had been incubated in a solution of TIC. Note that
a brick red precipitate was deposited on the cut surface of muscle
outside the area at risk. In addition, the precipitate was also
deposited on myocardium in the epicardial and lateral portions of
the area at risk, indicating that it was not infarcted. A large region of infarcted muscle involving the endocardial half of the area
at risk is identified by its failure to deposit the precipitate.
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tical analysis was also employed to evaluate differences between treatment groups in body weight, left ventricular mass, and the mass and proportion of the left ventricle at risk.

T-tests with a Bonferroni cor-

rection were used to determine the significance of differences in infarct size between groups {85, 86).
using the method of least squares.

Linear regressions were calculated
Hemodynamic data were evaluated

using a two-way analysis of variance with replications followed by
Duncan's Multiple Range Test.

This permitted canparisons between groups

at any individual time and comparisons within any group overtime.
values are expressed as the mean ± the standard error of the mean.

All

RESULTS

Mortality and Arhythmias
A total of 33 animals were studied.

One control animal and 2

acutely beta-blocked animals developed high degree AV block associated
with profound hypo tension and died within 2 hours of coronary occlusion.
Measurement of the size of the risk region and infarct size were not
possible in these animals.
ments were excluded.

Hemodynamic data obtained from these experi-

One control animal developed ventricular fibril-

lation 18 minutes after circumflex ligation and was defib:rillated within
25 seconds, with prompt restoration of hemodymanics to the levels seen
prior to fibrillation.

The incidence of ventricular tachycardia

(defined as 3 or more consecutive ventricular extrasystoles at a :rate
greater than 100 beats per minute) was 1oi, 36% and 60% in the three
groups, respectively.
cant.

These differences were not statistically signifi-

Similarly, no difference was seen between groups in the number of

ventricular extrasystoles recorded during the first half-hour following
circumflex occlusion.

Effects of Acute and Chronic Beta-blockade on Infarct Size
Measurement of the size of the risk region and of the myocardium
infa:rcted was possible in 30 of the dogs studied.
presented in Table 1.

The data obtained is

No difference was present between groups in body
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Table 1
RISK REGION AND INFARCT SIZES
Controls
(n=9)

Acutely
f3-blocked
(n=lO)

Chronically
f3-blocked
(n=ll)

Infarct mass
(g)

33.1±3.0
(18.9-45.1)

24.7±3.7
(2.4-39.8)

21.4±4.3
(0.4-38.0)

Risk region mass
(g)

48.2±2.9
(38.0-59.1)

46.1±2.9
(28.6-59.7)

47.1±2.0
(37.9-56.9)

103.0±4.5
(88. 6-117. 7)

105.7±4.6
(82.6-133.6)

103.6±2.6
(91. 9-114 .4)

Infarct/LV
(%)

32.0±2.6
(21-45)

22.7±3.2
(3-38)

20.6±4.2
(0-41)

Risk region/LV
(%)

46.9±2.4
(35-59)

43 .4±1.4
(35-51)

45.5±1.8
(34-54)

Infarct/risk region
(%)

67.7±2.9
(50-77)

51. 5±6. 6
(8-79)

43.5±8.3*
(1-80)

LV mass
(g)

Values are expressed as the mean ± s.e.m. (range in parentheses)
*p < .05 as compared with the control group.
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weight (group I • 19.2 ± 0.2 kg, group II • 20.4 ± 1.0 kg, group III •
20. 1 ± O. 3 kg), left ventricular mass, or in the mass of the risk region.

While the proportion of the left ventricle at risk in each group

was simila:r, a stepwise decrease in the mass infarcted and in the percent of the left ventricle infarcted was seen in groups II and III respectively.

When expressed as a proportion of the risk region, infarct

size was reduced 24j by acute beta-blockade and 36j by chronic betablockade.

The latter result was statistically significant as compared

with the control group.

However, differences in infarct size between

the acutely beta-blocked animals and either of the other two groups did
not :reach statistical significance.
In Figure 4 the percent of the left ventricle infarcted is plotted
as a function of the percent of the ventricle at risk, for the control
group.

A linear correlation with an R value of 0.90 was found (Y•.96x-

12. 98, P

<

.01 ).

By extrapolation, no infarction would be predicted

with risk :regions smaller than 14j of the left ventricle in this group.
Simila::r linear correlations were performed for acutely (Y•1. 58x-45. 71,
R•0.70, P

<

.05) and chronically (Y•1.72x-57.38, R•0.69, P

blocked animals.

<

.05) beta-

In general, the lines for these two groups were

shifted rightward, such that the mass of risk region necessary to produce an infarct of a given size was successively greater after acute and
chronic beta-blockade.

However, the much lower correlation coefficients

highlight the wide variability of infarct size in the drug treated
groups.
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Degree of Beta-blockade after Prolonged Oral Therapy and Infarct Size in
Chronically Beta-blocked Animals
All animals in g:roup 3 received the same daily dose of nadolol for
the same duration of time, and were of similar weights.

However, varia-

bil ity was present in the ch:ronot:ropic :response to the test dose of 2
uglkg of isoproterenol (0-30 bpm, mean•22 bpm) 12 hours after the last
oral dose of nadolol.

Similar variation was present in the supplemental

dose of i.v. nadolol (0-1. 3 mglkg, mean•O. 5 mgfkg) given just prior to
circumflex ligation to inhibit the increase in heart :rate after isop:roterenol to less than 10 bpm.

On the average, this supplemental dose of

i.v. nadolol was less than half that given to acute! y beta-blocked an imals (1-2.5 mgfkg, mean•1.3 mgfkg).

When the percent of the left ven-

tricle infarcted was plotted as a function of the ch:ronot:ropic :response
to isoproterenol, a statistically significant linear corr.elation was
found (Y•0.76x + 4.27, R•0.60, P

< .05).

Thus, the ability of nadolol

to limit infarct size after chronic oral therapy was in part a function
of the deg:ree of beta-blockade at the end of the 16 day treatment period.

This relationship was seen despite the fact that supplemental

doses of i.v. nadolol we:re given just p:rio:r to coronary occlusion to
ensure equivalent degrees of beta-blockade in all drug treated animals.

Hemodynamics Before and After Coronary Occlusion
Several measured and derived hemodynamic pa:ramete:rs obtained before and at three different times after circumflex ligation are presented in Table 2 and Figures 5 -7.

At all times heart rate in either of
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the drug treated groups was significantly less than in control animals.
Over the duration of the experiment heart :rate averaged 25 bpm higher in
control animals.

Six hours after coronary ligation heart :rate was 21

bpm greater than prior to coronary occlusion (p < .OS) in this group.
In contrast, heart rate was unchanged or minimally increased during the
experiment in groups II and III, :respectively.
Pre-occlusion left ventricular end diastolic pressures were
similar in all groups.

However, by 6 hours after circumflex occlusion

it was significantly elevated in control and acutely beta-blocked animals, as compared with pre-occlusion values.

LVEDP rose minimally in

chronically beta-blocked animals and was significantly less than in
either of the other two groups at 6 hours (p

<

.05).

There was no difference in dPldt among groups prior to coronary
occlusion.

Over the duration of the experiment, it :rose in control ani-

mals and declined in drug treated animals.

Six hours after circumflex

1 igation it was 36% and 26% lower, in groups II and III :respectively,

than in group I (p

< • 05).

Mean arterial pressure and left ventricular peak systolic pressure
were similar in all groups and essentially unchanged during the experiment as compared with pre-occlusion values.
product pa:ralelled those in heart rate.

Changes in rate pressure

At 6 hours it was 49% and 35%

greater in control animals than in acutely or chronically beta-blocked
animals, :respectively (p

< .05).

Table 2
HEMODYNAMIC DATA
TIME

GROUPS

Prior to
CFX
Occlusion

I
II
III

15 min
after
CFX Occl

II
III

2 hrs
after
CXF Occl
6 hrs
after
CXF Occl

I

I

II

III
I
II

III

HR
(BPM) -

MAP

LVEDP

LVPSP

(nunHg)

(mmHg)

(mmHg)

146.4+2.9
112+A.l
129.7+4.2* 109.8+4.l
128.1+3.8* 110 •. 6+3.9

4 .4+1. 2
6.1:+1.7
4.l+o.8

117. 7+6.5
119. 6+5 .o
121. 7+4.1

dP/dt
(mmHg/sec)

RPP/1000

1803+105
1764+142
1758+115

17·.'3+1. l
15.4+o.4
15.6+o.8

-

-

148.7+2.5
l24.6+4.0*
130. 5+4.1•

96.7+7.7
92.7:+5.3
99.3+3.6

8.3+2.0
10·.0+2. 2+
8. 2+1.1

108+8.9
1778+189
101. 8+4 .8+ . 1549+108
105.6+1.8
1598+123

16.5+2.2
12.6+o. 7*
14.l+o.7

158.9+6.2
120+5.5*
138.1+3.5#
*
167.4+6.8+
129.6+6.5•
142.1+5.3*

112.8+5.4
113.6+6.3
110.4+3.7

8. 7+1.5
12.4+2.3
9.0+1. 3

121. 8+6. l
120.7+5.3
119. 9+3. 2

1976+125
1517+89*
1649+81

19.5+1.6
14 .6+1. l*
16.5t-0.6

107.4+6.l
97.9+4.6
99.5+6.4

15.9+1.9+
15.8+2.6+
9.5:±1. 2~

124.7+5.5
108.9+3.7
111.4+5. 3

2020±112
1297±95+
1491+142•

21.1+1.5+
14. 2+i. O*
1S.8+o.8*

-

-

* p < .05 as compared with the control group
+ p < .05 as compared with the preocclusion value
H p < .05 as compared with the acutely B-blocked group
HR = Heart Rate,
Pressure, LVPSP
Left Ventricular

MAP = Mean Ar~erial Pressure, tVEDP = Left
= Left Ventricular Peak Systolic Pressure,
Pressure~

Ventricular End Diastolic
dD/dT = The Rate of Rise of
RPP/1000 = Rate Pressure Product t 1000

w

~
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FIGURE 4

INFARCT SIZE AS A.FUNCTION
OF 'IlIE AREA AT RISK
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FIGURE 4. The percent of the left ventricle infarcted increased as a
linear function of the size of the area at risk. Extrapolation of this
line to the X intercept indicates that no infarction \\Ould be expected
with risk regions snaller than 14% of the ventricle.
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FIGURE 5
HEARr RATE PRIOR 'IO AND AFI'ER
CX>RONARY CXXLUSION
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37
FIGURE 6

LVEDP PRIOR TO AND AFI'ER
CORONARY CXXllJSION
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FIGURE 7

d.P/dt PRIOR TO AND AFrER
OORONARY CX:U.USION
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DISCUSSION

Differences in Infarct Size and Potential Sources of Variability within
Groups
In this study acute and chronic beta-blockade resulted in incremental decreases in the proportion of the area at risk which infarcted
after circumflex ligation.

While a modest degree of variation in in-

farct size was seen in control animals, drug treated animals exhibited
much less uniformity.

Some dogs in both drug-treated groups evolved

infarcts as large as any in control animals while others derived marked
protection from beta-blockade.

As a result, only the reduction in in-

farct size achieved by prolonged beta-blockade was statistically significant as compared with the control group.

In addition, infarct sizes in

acutely and chronically beta-blocked animals did not significantly differ from each other.
The reason for the wide variability in the extent of myocardial
injury among animals in groups II and III is not clear.

In a recent

co-operative study, a group of investigatiors found that much of the
variation in infarct size in canine models of myocardial infarction
could be attributed to three independent variables (90).

The size of

the area at risk, collateral blood flow, and myocardial oxygen consumption (estimated by the rate-pressure product) accounted for roughly 70%,

15%, 5S of this variation, respectively.

To control for the most impor-

tant of these three variables, infarct size is commonly normalized
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for the size of the risk region, as was done in the present study.

In-

consistencies in accurate measurement of the risk region could produce
sufficient experimental error to make comparisons of normalized infarct
size between groups difficult.
not the case.

Two pieces of data suggest that this was

Figure 3 demonstrates that the technique employed in this

study accurately reproduces the finding of other investigators;
(19,22,24,25) the amount of the left ventricle infarcted increases linearly as a function of the size of the perfusion bed of the occluded
coronary artery.

In addition, the proportion of the left ventricle per-

fused by the circumflex, as defined by this technique, is very similar
to previously reported values (24, 87-90).

Therefore, variation in in-

farct size within or between groups cannot be ascribed to errors in
measuring the risk region.

Moreover, the average size of the area at

risk and variability about these means were similar in all three groups.
The fact that collateral blood flow into an ischemic region can
differ considerably between experimental animals has been observed repeatedly (25,26,90,91).

Its relative importance in determining the size

of experimental myocardial infarctions has only recently been determined.

Once the area at risk has been controlled for,

soi

of the re-

maining variability in infarct size in canine hearts is due to differences in collateral blood flow (90).
blood flow was not measured.

In the present study collateral

It would be anticipated that biologic

variation in collateral flow would affect all three groups equally if
the number of animals studied was sufficiently large.

The much wider

range in infarct size in drug-treated animals suggests that substantial
reductions in infarct size may only have occurred when collateral blood
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flow exceeded a minimal critical value.

In the absence of significant

collateral flow, neither acute nor chronic beta-blockade would be sufficient to maintain cellular viability for 6 hours after coronary occlusion.

This hypothesis is supported by the finding that beta-blockers

have been unsuccessful in reducing infarct size in species which lack a
significant coronary collateral circulation (39,47).
The severity of myocardial injury resulting from coronary occlusion depends upon the mismatch between oxygen supply and demand.

In

combination, the area at risk, collateral blood flow and the ratepressure product have been found to account for 90j of the variability
in infarct size seen in animals (90).

However, of these three, varia-

bility in myocardial oxygen consumption was the least important.

In

this experiment variation within groups in rate-pressure product was not
different and fails to account for the wider range of infarct size in
groups II and III.
By design, differences between animals in the degree of betablockade immediately prior to and during the 6 hour period of circumflex
occlusion were minimized.

A large dose of a very potent beta-blocker

was chosen and a supplemental dose was given before one half-life of
elimination.

Additionally, circumflex ligation in groups II and III

were performed only when sufficient beta-blockade was present to inhibit
the chronotropic responses to a large test dose of isoproterenol.

It

therefore seems unlikely that variation in the degree of beta-blockade
during the ischemic period contributed significantly to differences in
infarct sizes among drug-treated animals.
However, despite equivalent beta-blockade during coronary oc-
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clusion, infarct size in chronically beta-blocked animals was significantly correlated with the degree of beta-blockade (i.e. the inhibition
of the chronotropic response to isoproterenol) at the end of the 16 day
treatment period.

Differences between animals in the absorption, metab-

olism and elimination of nadolol are likely to have resulted in disparity in the magnitude of beta-blockade during this 16 day period.

This

was illustrated by the range of responses to the test dose of isoproterenol.

This finding suggests that "dose dependent" adaptive changes

may have occurred in the hearts of chronically beta-blocked animals
which conferred additional protection from ischemia induced injury.
Whether these adaptive changes were favorable alterations in metabolism
or in collateral blood flow is unknown.
In summary, although a number of potential sources for the wide
variation in infarct size among acutely and chronically beta-blocked
animals exist, two appear to have been particularly important.

In both

groups variability in collateral blood flow may have served a permissive
function such that significant reduction in infarct size may only have
occurred when collateral flow exceeded a critical minimal value.

In the

chronically beta-blocked animals the degree of beta-blockade during the
16 day treatment period was found to be an independent predictor of infarct size.

Mechanisms for the Protective Effect of Acute and Chronic Beta-Blockade
In animal models of myocardial infarction, dramatic increases in
cardiac sympathetic nerve activity (5) and in circulating levels of
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plasma catecholamines (6) have been demonstrated shortly after coronary
occlusion.

Striking elevations of plasma norepinephrine and epinephrine

concentrations have similarly been reported in patients with evolving
infarcts (92).

By enhancing the disparity between myocardial oxygen

supply and consumption, catecholamines have been shown to augment the
severity of cellular injury in ischemic tissues (7,93).

Beta-blockers

have been shown in experimental and clinical myocardial infarction to
decrease myocardial oxygen consumption and to favorably shift myocardial
metabolism from lactate production to lactate extraction (94-96).
Catecholamine mediated stimulation of beta-1 receptors leads to
increases in both heart rate and contractility.

If decreasing heart

rate alone was the only important action of beta-blockers, they would
still achieve the dual benefits of decreasing myocardial oxygen consumption and increasing the time available for diastolic perfusion of the
coronary circulation.

However, beta-blockers have been shown to protect

ischemic tissue independent of their negative chronotropic effects.
Hilis et al. (97) observed that when propranolol was administered to
dogs subjected to LAD occlusion, the resulting rise of intramyocardial
pC02 was 43j less than in control experiments.

Virtuallly the same pro-

tection was seen in animals paced to prevent beta-blocker mediated decreases in heart rate.

Similarly, Armstrong et al. (98) found that when

atrial pacing was performed in a group of patients with coronary artery
disease the threshold to angina and the electrocardiographic and metabolic indices of ischemia were all attenuated.
The enhanced sympathetic activity that accompanies acute myocardial infarction may also effect the severity of myocardial ischemia
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through indirect, extracardiac actions.

Catecholamines are lipolytic

and elevated levels of circulating free fatty acids have been demonstrated during myocardial infarction (92,99).

With elevation of free

fatty acids, substrate utilization within ischemic tissue shifts unfavorably from the anaerobic metabolism of glucose towards the oxidation
of free fatty acids (100).

Pharmacologic inhibition of catecholamine-

sensitive lipases has been shown to reduce infarct size in a canine
model (101).

By inhibiting the action of epinephrine on adipocytes,

beta-blockers have been shown to reduce circulating free fatty acids
during myocardial infarction in man (92).

The ability of beta-blockers

to reduce oxygen consumption in ischemic tissues may partially be due to
this action.
Another proposed effect of beta-blockers is that they improve
oxygen supply to ischemic myocardium by increasing collateral blood flow
(102).

While some studies have reported enhanced collateral flow (102)

and an increase in the ratio of endocardial to epicardial flow (103),
others have found no beneficial changes in regional myocardial blood
flow when beta-blockers were administered during experimental myocardial
infarction (37, 38).
In this experiment, measurement of the major determinants of myocardial oxygen consumption were made before and after coronary occlusion.

Pre-occlusion values of left ventricular end diastolic pres-

sure, mean arterial pressure, and dP/dt were not different between
groups.

Heart rate, however, was lower in beta-blocked animals.

Over

the course of the 6 hour experiment heart rate rose progressively in
control animals while changing little in the other groups.

This sug-

4 5

gests that the control group was exposed to progressively increasing
adrenergic stimulation in response to circumflex ligation.
Similarly, coronary occlusion produced directionally opposite
changes in dP/dt in control and beta-blocked animals.

Despite the fact

that 32 ± 2.6S of the left ventricle was infarcted in control animals,
the expected decline in dP/dt was not seen.

Instead dP/dt rose and was

significantly greater than in drug treated animals at 6 hours.

This

suggests that a marked augmentation of contractility occurred in the
non-ischemic myocardium of control animals.

It was of sufficient magni-

tude that dP/dt, an index of overall left ventricular contractile function, failed to decline as anticipated.

Higher heart rates, elevated

left ventricular end diastolic pressures, and greater levels of sympathetic tone in the control group, together may account for this phenomenon.

In combination, they also resulted in significantly larger myo-

cardial infarcts as compared with chronically beta-blocked animals.
All the potential mechanisms cited above for the salutary effects
of beta-blockade in acute myocardial infarction are pertinent to both
groups of drug-treated animals evaluated in this study.

As discussed

earlier, a series of studies have demonstrated alterations of myocardial
ultrastructure, metabolism efficiency of energy utilization and collateral blood flow afer prolonged interruption of cardiac adrenergic stimulation.

These effects could potentially confer added protection from

ischemia induced injury to chronically beta-blocked hearts.

Although

infarct size was not statistically different between drug treated
animals in this study, left ventricular end diastolic pressure was significantly less in chronically beta-blocked animals 6 hours after cir-
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cumflex ligation.
In the setting of acute myocardial infarction, loss of contractile
function by ischemic cardiac muscle leads to diminished ventricular
emptying during systole and elevated end diastolic volumes.

In ad-

dition, impaired relaxation of ischemic myocardium during diastole results in diminished left ventricular compliance.

Together systolic and

diastolic dysfunction result in elevation of left ventricular end diastolic pressure.

In the present study, systolic ventricular function in

chronically beta-blocked animals, as measured by dP/dt, was no different
than that in acutely beta-blocked animals and was less than that in the
control group 6 hours after coronary occlusion.

The finding that left

ventricualar end diastolic pressure was significantly lower in chronically beta-blocked animals than in either of the other

tw~

groups sug-

gests that left ventricular compliance may have been substantially
better in this group.

However, since left ventricular compliance was

not directly measured in this study, differences in compliance between
groups can only be inferred.

Comparisons with Earlier Studies
No previously published study has compared the effects of immediate and long-term beta-blockade on infarct size and hemodynamics
resulting from experimental coronary artery occlusion.

In two studies,

isolated, working hearts of small animals have been subjected to periods
of global ischemia or hypoxia at various times after cessation of prolonged beta-blocker therapy.

Manning et al. (73) found that the number
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of hearts that recovered mechanical function and the post-ischemic
cellular levels of creatine phosphate and glycogen were significantly
enhanced in rats previously treated with either propranolol or
oxprenolol.

Prolonged pre-treatment with propranolol resulted in less

CPK release, less mitochondrial calcium accumulation and enhanced mitochondrial function in rabbit hearts subjected to 60 minutes of hypoxic
perfusion by Nayler et al. (9).

In both of these studies, the protec-

tive effects of prior beta-blockade were seen at times when residual
drug levels or functional beta-blockade could not be demonstrated.

They

suggest that there are secondary consequences of long-term beta-blockade
which are beneficial during myocardial ischemia.
Two studies, both performed in rats, have evaluated the effects of
chronic beta-blockade on injury resulting from coronary ligation.
Hearse et al. (75) occluded the LAD in isolated, working hearts of rats
previously treated with acebutolol or propranolol for 2-3 weeks.

After

1 hour of ischemia cardiogreen dye was infused into the aortic root to
identify all myocardium perfused by native or collateral vessels.

They

found that the ischemic region, defined by the absence of green dye, was
substantially smaller in the hearts of chronically beta-blocked animals.
This implies that collateral blood flow in these hearts was enhanced.
However, high energy phosphate content within the ischemic region was
not different between groups and infarct size was not measured.

Re-

cently Campbell et al. (76) reported that chronic oxprenolol treatment
did not reduce the size of myocardial infarcts after ligation of the
left main coronary artery in rats.

It is doubtful that any intervention

would favorably alter infarct size with such a large proportion of the
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ventricle ischemic or in the presence of the marked tachycardia they
reported (400+ bpm).
Direct comparison between the present study and those cited above
are difficult.

None of these studies have investigated the effects of

acute and chronic beta-blockade on infarct size in the same model.

In

addition, heart rate, left ventricular internal diameter and wall thickness (all important determinants of myocardial oxygen consumption) are
drastically different in rat and rabbit models from that seen in the
canine heart.

In experimental design, the present study is much closer

to those which have evaluated the effects of cardiac denervation on infarct size and myocardial function in anesthetized dogs.
Jones et al. (10) ligated the apical portion of the anterior descending

and compared the proportion of the left ventricle infarcted in

control animals, those denervated just prior to coronary occlusion, and
those denervated 2 weeks previously.

They found sequential substantial

reductions in infarct size with acute and chronic cardiac denervation.
Using a similar model with coronary occlusion at the same site, Barber
et al. (61) reproduced these findings.

In contrast, the abilities of

acute and chronic beta-blockade to limit infarct size in the present
study were less dramatic.

This difference might be attributed to the

substantially larger risk regions in this study.

The area at risk was

not measured in the former studies but it appears to have been no larger
than 20-25% of the left ventricle.

In comparison, the area at risk was

nearly twice as large in this investigation.

It has previously been

demonstrated that even in control animals no infarction frequently
occurs with risk region less than 15-20% of the ventricle (22,25-27).
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Additionally, the ability of an intervention to limit infarct size increases substantially as the area at risk becomes smaller (22).
The relative effects of acute and chronic cardiac denervation on
myocardial contractile function after coronary occlusion were described
by Thomas et al. (64). They found substantial equivalent reductions in
epicardial contractile force after coronary ligation in control and
acutely denervated hearts.

However, the depression of regional myocar-

dial function seen in chronically denervated hearts was only one third
that seen in other groups.

Although regional myocardial function was

not measured in the present study, left ventricular end-diastolic pressure was significantly lower in chronically beta-blocked animals than in
other groups 6 hours after coronary occlusion.
Recently Lavallee et al. (68) reported larger myocardial infarcts
and higher left ventricular end diastolic pressures after proximal
circumflex ligation in concious, chronically denervatd dogs.

The reason

for the disparity between these results and earlier investigations of
the effects of cardiac devervation on infarct size, myocardial function
and arhythmias in anesthetized animals is not clear.

However, the work

of Lavallee et al. suggests that an avenue for future investigation
might include the repitition of the present study in conscious animals.

SUMMARY

In the present study, the relative effects of acute and chronic
beta-blockade on infarct size and hemodynamics after circumflex ligation
in anesthetized dogs were investigated.

In comparison with control

animals, mean infarct size was smaller in both groups of drug-treated
animals, but only the reduction in infarct size achieved by chronic
beta-blockade was statistically significant.

While infarct size among

the two groups of beta-blocked animals were similar, left ventricular
end diastolic pressure was significantly less 6 hours after coronary
occlusion in chronically beta-blocked animals.

The salutary effects of

beta-blockade in this study can partially be attributed to protection
from enhanced adrenergic tone after coronary occlusion.

Despite the

fact that all drug treated animals had similar and substantial degrees
of beta-blockade during coronary occlusion, infarct size in chronically
beta-blocked animals was independently correlated with the degree of
beta-blockade during the previous 16 days.
From these findings we conclude that long term beta-blockade results in at least as great a reduction in infarct size as does acute
beta-blockade.

However, left ventricular hemodynamics during myocardial

infarction, as evidenced by lower end-diastolic pressures, appear to be
better preserved after chronic beta-blockade.

In addition, the protec-

tive effect of prolonged beta-blockade during subsequent periods of myocardial ischemia is related to the degree of beta-blockade during the
50
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previous treatment period.
These findings support the current clinical practice of prolonged
beta-blocker therapy in patients at high risk for subsequent ischemic
events.

In addition, they suggest that patients may benefit from re-

ceiving the largest dose of beta-blockers tolerated without side
effects.
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